Decoy Therapeutics INC. (DCOY) — SEC Filings

Overview

Decoy Therapeutics INC. (DCOY) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 19, 2025: Salarius Pharmaceuticals, Inc. filed an 8-K on December 19, 2025, reporting on the submission of matters to a vote of security holders, Regulation FD disclosure, and financial statements/exhibits. The company, formerly known as Flex Pharma, Inc., is based in Houston, TX.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 8 bearish, 38 neutral, 4 mixed. The dominant filing sentiment for Decoy Therapeutics INC. is neutral.

Filing Type Overview

Decoy Therapeutics INC. (DCOY) has filed 1 S-8, 29 8-K, 4 10-Q, 3 DEF 14A, 7 S-1/A, 1 8-K/A, 1 10-K, 2 S-1, 1 SC 13G/A, 1 DEFA14A with the SEC between Nov 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• S-8 Filing — S-8 · Apr 2, 2026
• 8-K Filing — 8-K · Apr 2, 2026
• Salarius Pharmaceuticals Files 8-K — 8-K · Dec 19, 2025 Risk: low
  Salarius Pharmaceuticals, Inc. filed an 8-K on December 19, 2025, reporting on the submission of matters to a vote of security holders, Regulation FD disclosure
• Salarius Pharmaceuticals Announces Board and Executive Changes — 8-K · Nov 19, 2025 Risk: medium
  Salarius Pharmaceuticals, Inc. announced on November 18, 2025, changes in its board of directors and executive compensation arrangements. The filing details the
• 8-K Filing — 8-K · Nov 17, 2025
• Salarius Narrows Losses, Boosts Cash Post-Decoy Merger — 10-Q · Nov 14, 2025 Risk: high
  Salarius Pharmaceuticals, Inc. (DCOY) reported a net loss of $873,467 for the three months ended September 30, 2025, an improvement from a net loss of $972,121
• Salarius Pharmaceuticals Reports Multiple Material Events — 8-K · Nov 13, 2025 Risk: medium
  Salarius Pharmaceuticals, Inc. filed an 8-K on November 13, 2025, reporting several material events as of November 11, 2025. These include entering into a mater
• Salarius Pharma Sets Dec. 19 Annual Meeting, Board Backs All Proposals — DEF 14A · Nov 7, 2025 Risk: medium
  Salarius Pharmaceuticals, Inc. (DCOY) is holding its 2025 Annual Meeting of Stockholders on December 19, 2025, to address three key proposals. Stockholders will
• Salarius to Offer 1.96M Shares, Warrants for Decoy Merger — S-1/A · Oct 21, 2025 Risk: high
  Salarius Pharmaceuticals, Inc. (DCOY) filed an S-1/A on October 21, 2025, detailing a proposed offering of 1,960,784 shares of common stock, or pre-funded warra
• Salarius Pharmaceuticals Reports Director Changes and Compensation Updates — 8-K · Oct 21, 2025 Risk: medium
  Salarius Pharmaceuticals, Inc. filed an 8-K on October 21, 2025, reporting changes in its board of directors and executive compensation arrangements. The filing
• Salarius Pharmaceuticals Files 8-K — 8-K · Oct 14, 2025 Risk: low
  Salarius Pharmaceuticals, Inc. filed an 8-K on October 14, 2025, reporting other events and financial statements as of October 10, 2025. The company, formerly k
• Salarius Pharmaceuticals Files 8-K — 8-K · Oct 6, 2025 Risk: medium
  Salarius Pharmaceuticals, Inc. filed an 8-K on October 6, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these
• Salarius Seeks $6M to Seal Decoy Merger, Nasdaq Listing Hinges on Shareholder Vote — S-1/A · Sep 23, 2025 Risk: high
  Salarius Pharmaceuticals, Inc. (DCOY) is offering 1,518,027 shares of common stock, Series A Warrants, and Series B Warrants at an assumed combined public offer
• Salarius Pharmaceuticals Files 8-K — 8-K · Sep 18, 2025 Risk: medium
  Salarius Pharmaceuticals, Inc. filed an 8-K on September 17, 2025, reporting on a material definitive agreement, modifications to security holder rights, and fi
• Salarius Pharmaceuticals Changes Office Address — 8-K · Sep 9, 2025 Risk: low
  Salarius Pharmaceuticals, Inc. filed an 8-K on September 9, 2025, reporting an event on September 4, 2025. The filing indicates a change in the company's princi
• Salarius Pharmaceuticals Files 8-K: "Other Events" — 8-K · Aug 27, 2025 Risk: medium
  Salarius Pharmaceuticals, Inc. filed an 8-K on August 27, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these
• Salarius Pharmaceuticals Files 8-K/A Amendment — 8-K/A · Aug 26, 2025 Risk: low
  Salarius Pharmaceuticals, Inc. filed an 8-K/A on August 26, 2025, to amend a previous filing. The amendment pertains to financial statements and exhibits, with
• Salarius Pharmaceuticals Files 8-K — 8-K · Aug 22, 2025 Risk: low
  Salarius Pharmaceuticals, Inc. filed an 8-K on August 22, 2025, to report other events and financial statements. The company, formerly known as Flex Pharma, Inc
• Salarius Pharmaceuticals Board Shake-up — 8-K · Aug 18, 2025 Risk: medium
  Salarius Pharmaceuticals, Inc. announced on August 17, 2025, a change in its board of directors. Specifically, Dr. Jeffrey T. Vaught has resigned from his posit
• Salarius Pharmaceuticals Files 8-K with Key Corporate Updates — 8-K · Aug 15, 2025 Risk: medium
  Salarius Pharmaceuticals, Inc. filed an 8-K on August 15, 2025, reporting material modifications to security holder rights and other events. The filing also inc
• Salarius Posts Q2 Net Loss of $5.5M, Continues Equity Funding — 10-Q · Aug 12, 2025 Risk: high
  Salarius Pharmaceuticals, Inc. (DCOY) reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, indicating i
• Salarius Pharma Updates S-1/A, Reports $5.5M Net Loss in 2024 — S-1/A · Aug 8, 2025 Risk: high
  Salarius Pharmaceuticals, Inc. (DCOY) filed an S-1/A on August 8, 2025, updating its business and financial information and responding to SEC comments. The comp
• Salarius Faces Mounting Losses, Seeks Fresh Capital Amid S-1/A Filing — S-1/A · Jul 31, 2025 Risk: high
  Salarius Pharmaceuticals, Inc. (DCOY) filed an S-1/A on July 31, 2025, updating its business and financial information and responding to SEC comments. The compa
• Salarius Pharmaceuticals Files 8-K on Operations and Equity Sales — 8-K · Jul 31, 2025 Risk: medium
  On July 31, 2025, Salarius Pharmaceuticals, Inc. filed an 8-K report detailing results of operations and financial condition, as well as unregistered sales of e
• Salarius Pharmaceuticals Files 8-K — 8-K · Jul 29, 2025 Risk: medium
  Salarius Pharmaceuticals, Inc. filed an 8-K on July 29, 2025, reporting on material definitive agreements and modifications to security holder rights. The filin
• Salarius Pharmaceuticals Relocates Offices — 8-K · Jul 28, 2025 Risk: low
  On July 28, 2025, Salarius Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 2450 Holcomb
• Salarius Pharmaceuticals Files 8-K: Material Agreement & Security Holder Changes — 8-K · Jul 21, 2025 Risk: medium
  On July 18, 2025, Salarius Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The filing also indicates modifications to the rights of security
• Salarius Pharmaceuticals Files 8-K — 8-K · Jul 14, 2025 Risk: low
  Salarius Pharmaceuticals, Inc. filed an 8-K on July 14, 2025, reporting other events and financial statements as of July 10, 2025. The company, formerly known a
• Salarius Pharmaceuticals Reports Shareholder Vote Matters — 8-K · Jul 8, 2025 Risk: low
  Salarius Pharmaceuticals, Inc. filed an 8-K on July 8, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's
• Salarius Narrows Losses to $16.7M, Extends Runway to Q3 2025 — S-1/A · Jun 16, 2025 Risk: high
  Salarius Pharmaceuticals, Inc. (DCOY) filed an S-1/A on June 16, 2025, updating its business and financial information. The company reported a net loss of $16.7
• Salarius Pharmaceuticals Files 8-K — 8-K · Jun 16, 2025 Risk: medium
  Salarius Pharmaceuticals, Inc. filed an 8-K on June 16, 2025, reporting an event on June 11, 2025. The filing is categorized under 'Other Events' and does not p
• Salarius Pharmaceuticals Files 8-K — 8-K · Jun 11, 2025 Risk: medium
  Salarius Pharmaceuticals, Inc. filed an 8-K on June 11, 2025, reporting a material definitive agreement and financial statements. The filing indicates a change
• Salarius Seeks Reverse Split, Capital Infusion to Bolster Nasdaq Listing — DEF 14A · May 27, 2025 Risk: high
  Salarius Pharmaceuticals, Inc. (DCOY) filed a DEF 14A on May 27, 2025, outlining proposals for a Special Meeting of Stockholders on July 8, 2025. The primary ag
• Salarius Narrows Loss to $19.9M, Seeks Fresh Capital for Drug Trials — S-1/A · May 22, 2025 Risk: high
  Salarius Pharmaceuticals, Inc. (DCOY) filed an S-1/A on May 22, 2025, updating its business and financial information and responding to SEC comments. The compan
• Salarius Pharmaceuticals Files Preliminary Proxy Statement — DEF 14A · May 15, 2025 Risk: low
  Salarius Pharmaceuticals, Inc. filed a preliminary proxy statement on May 15, 2025, for its annual meeting. The filing indicates no fee was required for this su
• Salarius Pharmaceuticals Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: medium
  Salarius Pharmaceuticals, Inc. filed a 10-Q for the period ending March 31, 2025. The company, formerly known as Flex Pharma, Inc., is based in Houston, TX. Fin
• Salarius Pharmaceuticals Faces Delisting Notice — 8-K · Apr 25, 2025 Risk: high
  Salarius Pharmaceuticals, Inc. filed an 8-K on April 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, form
• Salarius Pharmaceuticals Files S-1/A Update — S-1/A · Apr 17, 2025 Risk: medium
  Salarius Pharmaceuticals, Inc. filed an S-1/A on April 17, 2025, to update its business and financial information and respond to SEC comments. The company, form
• Salarius Pharmaceuticals Faces Delisting Concerns — 8-K · Mar 28, 2025 Risk: high
  Salarius Pharmaceuticals, Inc. filed an 8-K on March 28, 2025, reporting a material definitive agreement and a notice of delisting or failure to meet continued
• Salarius Pharmaceuticals Files 2024 10-K — 10-K · Mar 21, 2025 Risk: medium
  Salarius Pharmaceuticals, Inc. filed its 2024 10-K on March 21, 2025, detailing its financial performance for the fiscal year ending December 31, 2024. The comp
• Salarius Pharmaceuticals Files 8-K — 8-K · Mar 11, 2025 Risk: low
  Salarius Pharmaceuticals, Inc. filed an 8-K on March 11, 2025, reporting on events that occurred on March 10, 2025. The filing includes financial statements and
• Salarius Pharmaceuticals Files S-1 for Potential Stock Offering — S-1 · Jan 21, 2025 Risk: medium
  Salarius Pharmaceuticals, Inc. filed an S-1 form on January 21, 2025, indicating a potential offering of securities. The company, formerly known as Flex Pharma,
• Salarius Pharmaceuticals Files 8-K on Operations and Equity Sales — 8-K · Jan 17, 2025 Risk: medium
  Salarius Pharmaceuticals, Inc. filed an 8-K on January 17, 2025, reporting on its results of operations and financial condition, as well as unregistered sales o
• 8-K Filing — 8-K · Jan 13, 2025
• Salarius Pharmaceuticals Files 8-K on Shareholder Vote Matters — 8-K · Dec 23, 2024 Risk: medium
  Salarius Pharmaceuticals, Inc. filed an 8-K on December 23, 2024, reporting on matters submitted to a vote of security holders as of December 20, 2024. The fili
• Salarius Pharmaceuticals Files S-1 for Potential Securities Offering — S-1 · Dec 16, 2024 Risk: medium
  Salarius Pharmaceuticals, Inc. filed an S-1 registration statement on December 16, 2024, to register an unspecified number of securities. The company, formerly
• Salarius Pharmaceuticals Files 8-K with Material Agreement — 8-K · Dec 13, 2024 Risk: medium
  On December 12, 2024, Salarius Pharmaceuticals, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing.
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Salarius Pharmaceuticals Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: medium
  Salarius Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Flex Pharma, Inc., reported financial res
• Salarius Pharmaceuticals Files Proxy Materials — DEFA14A · Nov 1, 2024 Risk: low
  Salarius Pharmaceuticals, Inc. filed a Definitive Additional Materials proxy statement on November 1, 2024. This filing is related to their annual meeting and l

Risk Profile

Risk Assessment: Of DCOY's 45 recent filings, 11 were flagged as high-risk, 23 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Decoy Therapeutics INC.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: $0
• Net Income: $ -873,467
• EPS: $ -1.81
• Debt-to-Equity: 0.43
• Cash Position: $ 4,809,680
• Operating Margin: -100.0%
• Total Assets: $ 6,097,032
• Total Debt: $ 1,848,967

Key Executives

• Mark J. Rosenblum
• Annie Yan
• Andrew L. Strong, Esq.
• Stephen M. Nicolai, Esq.
• Jeffrey Kuras, Esq.
• Michael Nertney, Esq.
• Dr. Jeffrey T. Vaught
• Dr. David M. E. Chew
• Mr. Robert L. W. Smith
• institutional investor
• Board of Directors
• David J. Arthur

Industry Context

The biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on external financing to fund operations until a product generates revenue. The increasing adoption of AI in drug discovery and development is a key trend, promising to accelerate preclinical stages and improve success rates, but also intensifying competition.

Top Tags

Biotechnology (9) · financials (7) · material-agreement (6) · filing (5) · corporate-filing (4) · equity-sale (4) · 8-K (4) · financial-reporting (4) · corporate-action (4) · Net Loss (4)

Key Numbers

• SEC File Number: 001-36812 — Identifies the company's filing with the SEC.
• IRS Employer Identification Number: 46-5087339 — Unique identifier for tax purposes.
• Cash and Cash Equivalents: $4.8M — Increased from $2.4M at Dec 31, 2024, providing short-term liquidity.
• Net Loss (Q3 2025): $873K — Improved from $972K in Q3 2024, indicating a slight reduction in operational burn.
• Net Loss (9 months 2025): $3.5M — Lower than $4.1M in 9 months 2024, showing a trend of reduced losses.
• Research and Development Expenses (Q3 2025): $61.8K — Significantly down from $137.2K in Q3 2024, reflecting a shift in R&D strategy or pipeline focus.
• Proceeds from Equity Issuances: $6.4M — Primary source of increased cash, crucial for funding operations.
• Accumulated Deficit: $85.4M — Highlights the company's history of losses and lack of profitability.
• Common Shares Outstanding: 5,862,178 — As of November 12, 2025, post-reverse stock splits.
• Reverse Stock Split: 1-for-15 — Effected August 15, 2025, to maintain Nasdaq listing compliance.
• Reverse Stock Split Ratio: 1-for-15 — Occurred on August 15, 2025, impacting share structure
• Shares of Common Stock Outstanding: 1,051,782 — As of the Record Date, October 24, 2025, entitled to vote
• Annual Meeting Date: December 19, 2025 — Date when stockholders will vote on proposals
• Record Date: October 24, 2025 — Date for determining stockholders entitled to vote
• Director Term End Year: 2028 — Class I directors will serve until the 2028 Annual Meeting

Related Companies

SLRX

Frequently Asked Questions